Testing new drugs for tumors caused by NF2-related schwannomatosis
Official title: Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study tests whether new drugs can help people with NF2-related schwannomatosis, a condition that causes tumors in the nerves and brain.
Read our full plain-language summary
What the trial team says
This is an adaptive platform-basket trial that aims to evaluate the safety and efficacy of multiple novel agents and combination therapies in patients with NF2-related schwannomatosis (NF2-SWN). The study employs a basket design to assess treatment responses across four tumor types commonly associated with NF2-SWN: vestibular schwannomas, non-vestibular schwannomas, meningiomas, and ependymomas. A shared natural history observational cohort, receiving routine clinical follow-up without investigational treatment, serves as a common control for all substudies. The adaptive platform enables the dynamic addition or closure of substudies based on interim analyses, thereby optimizing trial efficiency. Eligible patients who meet the master protocol criteria and satisfy substudy-specific safety requirements will be assigned to receive the corresponding intervention. Currently open substudies include: * Substudy A: Selumetinib * Substudy B: Luvometinib plus Serplulimab
Key facts
- Registry number
- NCT07713745
- Stage of testing
- Phase 2
- Conditions studied
- Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma, NF2-related Schwannomatosis, NF2
Where it is running
This trial lists 5 sites.
-
Beijing Municipality
- Xuanwu Hospital, Capital Medical University (Beijing)
- Beijing Tiantan Hospital, Capital Medical University (Beijing)
- Chinese PLA General Hospital (Beijing)
-
Jilin
- The First Hospital of Jilin University (Changchun)
-
Shanghai Municipality
- Shanghai General Hospital (Shanghai)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.